The hypothesis that myelin alterations play a critical role in the development of psychosis is receiving increasing scientific interest. Studies also suggest that dopamine antagonists, particularly long-acting injectables, are associated with a remyelination effect and that this effect is correlated with improvement in clinical symptoms in patients with schizophrenia, as reported at WSFBP Virtual 2021.
"It has been hypothesised that myelin alterations are a critical factor in the development of psychosis, and there is increasing evidence for a central role of white matter pathologies in schizophrenia", explained Professor Paolo Brambilla, University of Milan, Pathophysiology and Transplantation, Italy.
Myelin alterations could be critical in the development of psychosis
Abnormal white matter integrity has been reported among drug-naïve, first episode schizophrenia patients and has been associated with negative symptoms and cognitive impairment.1
More specifically, psychotic symptoms in patients with schizophrenia have been associated with integrity of the frontal fasciculi, and in these patients, six weeks of short-acting dopamine receptor blockade had a remyelinating effect, normalizing the white matter.2
Study suggests that dopamine antagonists, particularly long-acting injectables, are associated with a remyelination effect
Long-acting injectables may have a more pronounced effect on white matter
Long-acting injectables (LAIs) may have a more pronounced effect on white matter volume than oral antipsychotics. In a study evaluating frontal lobe white matter volume after six months of treatment with a LAI or an oral antipsychotic, the volume of frontal lobe white matter remained stable in patients treated with the LAI but decreased in those treated with the oral antipsychotic.3
Increased myelination correlates with improvement in negative symptoms
These myelination effects are clinically meaningful, as was demonstrated in preliminary results of a study from Professor Brambilla’s group, which evaluated changes in symptomology in 10 patients with affective and non-affective psychosis, who were treated with an LAI, and the correlation with myelin water fraction changes over 12 months.
Results showed that reductions in negative symptoms evaluated by the Positive and Negative Syndrome Scale (PANSS) correlated with increased myelination in several regions of the brain over time, including in the corpus callosum, the internal capsule, and particularly, in the inferior frontal occipital fasciculus.4
Increased myelination correlated with improvements in the PANSS
Many psychotropic treatments ranging from lithium and antipsychotics to serotonin reuptake inhibitors and acetylcholinesterase inhibitors have been shown to be efficacious in a wide spectrum of psychiatric disorders ranging from autism, schizophrenia, depression and bipolar. This may indicate that psychiatric symptoms and treatments may share a common mechanism, making myelin a potential novel and innovative therapeutic target in psychiatry.5
WFSBP: World Federation of Societies of Biological Psychiatry
BE-NOTPR-0076; approval date 08/2021
